Lixisenatide, the Type II diabetes molecule discovered by Zealand Pharma A/S, met the primary endpoint in the first Phase III combination trial. (BioWorld International)

Agennix AG grossed €78.4 million (US$107.8 million) – about €76 million net of expenses – in a combined rights offering and private placement that will enable it to continue development of its lead drug candidate, talactoferrin, which is being studied in cancer and sepsis. (BioWorld Today)

Shares in Actelion Pharmaceuticals Ltd. dropped by almost 8 percent Monday on news that clazosentan failed to reach the primary endpoint in a Phase III pivotal trial in patients who had undergone surgical clipping to treat a form of stroke called aneurysmal subarachnoid hemorrhage (aSAH). (BioWorld International)